Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate, were recently guests on Benzinga's All Access.
Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer.
Cingulate was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301.
